20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) operates in the BIOTECHNOLOGY industry and is headquartered in Victoria, Canada with about 49 employees. Its market capitalization is roughly $451 million. In the fiscal year ended 2025-12-31, EPRX reported $0M in revenue and ($39M) in net income.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
| Gross Profit | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($57M) | ($38M) | ($27M) | ($21M) | ($18M) | ($18M) | ($2M) | ($7M) | ($12M) | ($5M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($50M) | ($39M) | ($26M) | ($21M) | ($18M) | ($24M) | ($4M) | ($7M) | ($13M) | ($4M) |
| Net Margin % | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($50M) | ($38M) | ($25M) | ($21M) | ($18M) | ($18M) | ($2M) | ($6M) | ($15M) | ($5M) |
| Earnings Per Share (EPS) | $-0.94 | $-0.97 | $-0.75 | $-0.88 | $-0.96 | $-1.93 | $-0.31 | $-0.57 | $-1.03 | $-0.34 |
| Shares Outstanding (M) | 66M | 40M | 34M | 24M | 19M | 12M | 13M | 13M | 13M | 13M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M | — | — | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($18M) | ($16M) | ($16M) | ($7M) | ($8M) | ($7M) | ($7M) | ($6M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($14M) | ($13M) | ($17M) | ($6M) | ($9M) | ($7M) | ($7M) | ($6M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($14M) | ($13M) | ($17M) | ($6M) | ($9M) | ($7M) | ($7M) | ($6M) |
| Earnings Per Share (EPS) | $-0.22 | $-0.22 | $-0.32 | $-0.17 | $-0.24 | $-0.19 | $-0.20 | $-0.17 |
| Shares Outstanding (M) | 66M | 57M | 52M | 37M | 36M | 36M | 36M | 36M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($36M) | ($29M) | ($30M) | ($16M) | ($14M) | ($12M) | $0M | ($5M) | ($8M) | ($5M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($37M) | ($30M) | ($30M) | ($16M) | ($15M) | ($12M) | $0M | ($5M) | ($8M) | ($6M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($13M) | ($10M) | ($10M) | ($3M) | ($8M) | ($6M) | ($6M) | ($8M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($13M) | ($10M) | ($10M) | ($3M) | ($8M) | ($6M) | ($6M) | ($8M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $140M | $86M | $35M | $15M | $26M | $31M | $1M | $3M | $3M | $6M |
| Cash & Cash Equivalents | $52M | $81M | $33M | $15M | $25M | $21M | $0M | $1M | $1M | $4M |
| Total Liabilities | $10M | $6M | $3M | $15M | $16M | $12M | $23M | $21M | $14M | $1M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $8M | $9M | $7M | $13M | $12M | $4M | $0M |
| Total Shareholders' Equity | $131M | $82M | $33M | $2M | $11M | $20M | ($21M) | ($18M) | ($11M) | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EPRX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms